Zhimeng Biopharma’s investigational drug approved to begin phase 2 epilepsy clinical trial in China
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
The company has received approval from DCGI to begin patient enrolment and dosing in the country
Under the partnership, the Pfizer INDovation program will empower DPIIT-recognized startups with grants of up to Rs. 60 lakhs each, along with a tailored 18-month incubation program delivered by Social Alpha
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
The medicine was well tolerated, with no unexpected safety issue
This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity
Subscribe To Our Newsletter & Stay Updated